Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 19/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18154554 | 0.97 | MCHR1 (0.55) | MCHR1 | |
| Maleic Acid SCHEMBL21981711 | 0.91 | MCHR1 (0.50) | MCHR1 | |
| SCHEMBL30701156 | 0.88 | MCHR1 (0.57) | MCHR1 | |
| SCHEMBL18154534 | 0.88 | MCHR1 (0.57) | MCHR1 | |
| SCHEMBL18154561 | 0.87 | MCHR1 (0.54) | MCHR1 | |
| SCHEMBL18154521 | 0.86 | MCHR1 (0.54) | MCHR1 | |
| SCHEMBL30701057 | 0.86 | MCHR1 (0.54) | MCHR1 | |
| SCHEMBL18154574 | 0.85 | MCHR1 (0.54) | MCHR1 | |
| SCHEMBL18154522 | 0.84 | MCHR1 (0.62) | MCHR1 | |
| SCHEMBL30700913 | 0.84 | MCHR1 (0.62) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023242810-A1 | MCHR1 ANTAGONISTS FOR THE TREATMENT OF PRADER-WILLI SYNDROME | RICHTER GEDEON NYRT. (HU) | 2023-12-21 | — | — | WO | claimed |
| EP-3286193-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2020-05-27 | — | — | EP | claimed |
| US-10329296-B2 | Indole derivatives | RICHTER GEDEON NYRT. (HU) | 2019-06-25 | — | — | US | claimed |
| EP-3286193-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2018-02-28 | — | — | EP | claimed |
| WO-2016166684-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2016-10-20 | — | — | WO | claimed |
| WO-2023242810-A1 | MCHR1 ANTAGONISTS FOR THE TREATMENT OF PRADER-WILLI SYNDROME | RICHTER GEDEON NYRT. (HU) | 2023-12-21 | — | — | WO | disclosed |
| EP-3286193-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2020-05-27 | — | — | EP | disclosed |
| US-10329296-B2 | Indole derivatives | RICHTER GEDEON NYRT. (HU) | 2019-06-25 | — | — | US | disclosed |
| EP-3286193-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016166684-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329296-B2 | Indole derivatives | TPH1, MCHR1, MC1R | MCHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.